Actively Recruiting
Evaluating Navlimetostat Alone or with Izalontamab Brengitecan for Advanced NSCLC with MTAP Deletion After Prior Therapies
Led by Bristol-Myers Squibb · Updated on 2026-09-18
182
Participants Needed
67
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Navlimetostat BMS-986504 alone or together with Izalontamab Brengitecan in adults with advanced or metastatic Non-small Cell Lung Cancer NSCLC who have a specific genetic change called homozygous MTAP deletion or MTAP loss. Participants have experienced disease progression despite prior treatments. This is a Phase 2 randomized, open-label trial sponsored by Bristol-Myers Squibb. Participants receive either Navlimetostat alone at one of two doses or in combination with Izalontamab Brengitecan at one of two doses. The study is designed with sequential treatment groups and evaluates these treatments after prior therapies have failed. Dosing details are specified for each drug on designated days, and the study includes assessments to confirm genetic status before treatment. Throughout the study, participants undergo evaluations for tumor response using RECIST criteria, safety monitoring for adverse events including serious reactions up to 28 days after treatment ends, and quality of life assessments related to NSCLC symptoms. The primary outcome focuses on objective tumor response, with follow-up extending up to three years after the last dose. Participants health and laboratory tests are closely monitored during and after treatment to assess safety and efficacy.
CONDITIONS
Brief Title
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here